Starpharma Holdings Ltd (SPL)
Australian Securities Exchange · Australia · prices in AUD · close of 23 Oct 2026
Key indicators
| Last close | AUD 0.465 |
|---|---|
| 52-week range | 0.295 – 0.875 |
| Return, 1 month / 3 months | −42.9% / −33.1% |
| Return, 1 year / 3 years | +50.0% / +244.4% |
| Trend | Below its 200-day average |
| RSI (14) | 17 |
| Volatility (1 year) | 80.5% |
| Worst drawdown (1 year) | -46.6% |
| Average daily value traded | 1.97M AUD |
| Dividend yield | – |
Market X-Ray price-based
Five-year price chart navy: price · brown: 200-day average
About the company
Starpharma Holdings is an Australian pharmaceutical company based in Melbourne that develops products built on dendrimer chemistry. Its main offering is VivaGel, a gel used to help prevent bacterial vaginosis and certain sexually transmitted infections, sold for women's health. The company also applies its dendrimer platform to drug delivery, working with partners to improve how medicines are formulated and released, and to agricultural and other specialty applications. Its customers are mainly healthcare consumers, medical partners and licensing collaborators.
Starpharma Holdings Ltd trades under the code SPL on the Australian Securities Exchange in Australia, with its price quoted in Australian dollars (AUD). Our records, which start in 2019, show no dividend payments for it. The Market X-Ray on this page is price-based and compares it with other stocks on the same exchange; it does not measure how healthy the business is.
Summary
Starpharma Holdings Ltd (SPL) trades on the Australian Securities Exchange in Australia. It last closed at AUD 0.465 on 23 October 2026.
Its price-based Market X-Ray is 58 out of 100 (a fair price profile), ranking 735 of 1,816 stocks on this exchange. The score describes how the stock has traded: trend, momentum, risk, liquidity and dividends, each ranked against the other stocks on its own exchange. It does not measure how healthy or cheap the business is.
Over the last year the price rose 50.0% and over the last three months it fell 33.1%. Returns are price returns, dividends not included.
Fundamental measures (valuation, growth, financial health) are not shown: we do not yet hold financial statements for this market.
The five lenses in numbers each metric is ranked against the other stocks on Australian Securities Exchange
| Lens and metric | Value | Score | Reading |
|---|---|---|---|
| Trend | 58 · Fair | Mixed trend against its averages. | |
| Above 200-day average | -26.5% | ||
| From 52-week high | -46.6% | ||
| Momentum | 47 · Weak | Lagging most stocks on this exchange. | |
| 3-month return | -33.1% | ||
| 6-month return | -36.3% | ||
| 12-month return, skipping the last month | 162.9% | ||
| Stability (higher is calmer) | 53 · Fair | Typical risk for this exchange. | |
| Volatility, 1 year (lower is calmer) | 80.5% | ||
| Worst drawdown, 1 year (smaller is calmer) | -46.6% | ||
| Liquidity | 83 · Strong | Trades actively. | |
| Average daily value traded | 1.97M AUD | ||
| Zero-volume days | 3.3% | ||
| Income | – | Pays no dividend. | |
| Dividend yield | – | ||
| Years with dividends | 0 |
Strengths
- Liquidity: Trades actively.
Weak spots
- Momentum: Lagging most stocks on this exchange.
Returns
| 1 week | −38.0% |
|---|---|
| 1 month | −42.9% |
| 3 months | −33.1% |
| 6 months | −36.3% |
| 1 year | +50.0% |
| 3 years | +244.4% |
| 5 years | −57.7% |
Signals
| 50-day / 200-day average | 0.752 / 0.633 |
|---|---|
| Golden / death cross (60 days) | None |
| New 52-week high | No |
| Bullish RSI divergence | No |
| Average daily range (ATR) | 0.047 |
Technical summary
How to read this report
Every number comes from end-of-day prices and dividends. The Market X-Ray describes how the stock has traded, ranked against the other stocks on Australian Securities Exchange; it does not measure how healthy or cheap the business is. The fundamental X-Ray (financial health, valuation, growth) needs financial statements, which we hold today for US stocks. See the methodology page. Educational only, not financial advice.